
Opinion|Videos|March 18, 2024
Adverse Event Management of CAR-T in R/R MM
Author(s)Binod Dhakal, MD, MS
Binod Dhakal, MD, explores clinicians' safety concerns with using CAR-T therapy in R/R MM, including notable adverse events from recent clinical data and strategies for managing these events in practice.
Advertisement
Episodes in this series

Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Accepts BLA for Ivonescimab in Pretreated EGFR-Mutated NSCLC
2
NCCN Updates Breast Cancer Guidelines: Sacituzumab Govitecan for 1L TNBC
3
Multiomic Real-World Data Predict Outcomes in Metastatic Breast Cancer
4
FDA Grants FTD to GPRC5D Bispecific LBL-034 for R/R Multiple Myeloma
5


















